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Abstract
Primary atypical carcinoid of the breast is rare. Herein we present a case of atypical carcinoid of the breast treated
with surgery. The management plan is commented. Moreover an overview of the current evidence is presented.
All the evidence is classified as level IV (opinion-based evidence) since there is no satisfactory case series to
support a certain therapeutic decision. The treatment for an atypical carcinoid of the breast is the same one
offered in patients diagnosed with primary infiltrating breast cancer. A multi-centric approach is needed in order to
gather enough data to confidently support a certain management plan for these patients.
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Background
Primary atypical carcinoid of the breast is considered a
discrete histological entity reported in the WHO classifi-
cation within the group of neuroendocrine breast
tumors [1]. The exact percentage of primary breast car-
c i n o i d si su n k n o w n .A p p r o x i m a t e l y4 0 %o ft h eb r e a s t
carcinoids are metastatic from sites well known to have
neuroendocrine tissue, mainly lung, small bowel and
appendix [2,3]. The rest are supposed to be primary car-
cinoids. However, a thorough patient investigation is
needed in order to exclude an occult primary elsewhere.
Evidence regarding primary atypical breast carcinoid
management is short, since this subtype of neuroendo-
crine breast neoplasms is considered rather rare. This
does not permit large case-series to be studied and sig-
nificant conclusions to be produced.
Herein, a case of primary atypical breast carcinoid is
presented. Following a Pubmed search, we summarize in
brief the existing evidence on the field as assistance to
professionals that come up across that kind of neoplasm.
Case presentation
The patient gave her informed consent in order for her
case to be presented.
A 73-year old postmenopausal woman presented with
a small nodule on the left upper medial quadrant on a
routine mammography. Her medical and surgical his-
tories were null; no family history of any malignancy
was reported as well. This nodule was not detected on
clinical examination, whereas no axillary lumph nodes
were palpated. Breast ultrasound scanning verified the
existence of a solid nodule. The patient was admitted to
our department for a j-wire excisional biopsy. Routine
laboratory tests and CEA, CA15-3, CA125 and CA19-9
were within normal limits.
Histology of the specimen (Figure 1) revealed a tumor
measuring 1.1 cm in maximal diameter. The cut surface
appeared whitish while the tumor had a nodular config-
uration and was hard on palpation. Microscopically the
tumor was made up mostly of ovoid to round cells with
variation in size, granular eosinophilic cytoplasm and
nuclear pleomorhism arranged in irregular compact
nests, distinct trabeculae or insular pattern of growth.
Focally rosette formation was observed. Mitoses were
relatively sparse. The intervening stroma was collage-
nised, in some areas heavily. Immunohistochemistry was
positive for synaptophysin and chromogranin. There
was no evidence of vascular or lymphatic invasion. The
Hematoxylin-Eosin morphology assisted by the immu-
nohistochemical expression profile confirmed the diag-
nosis of a carcinoid tumor with atypical features.
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stemming from a primary neuroendocrine tumor located
elsewhere, a total body scan was performed after an
intravenous administration of 6 mCi In
111 -D T P A-
ocreotide. There was no evidence of increased expres-
sion of somatostatin receptor subtype 2, subtype 3 and
subtype 5 throughout the patient’s body (Figure 2).
Having ensured the diagnosis of a primary atypical
carcinoid of the breast, the findings were discussed in
the breast cancer multidisciplinary team (MDT) meeting
in the view of deciding management options. A modi-
fied radical mastectomy combined with left axillary
lymph node dissection (ALND), along with the decision
for no further treatment in case of a negative result, was
made.
Indeed the histology of the breast and of the 17 lymph
nodes removed during the ALND showed no evidence of
residual disease or metastatic spread and thus the patient
was referred back to our unit for routine follow-up.
Four years post-operatively, the patient is in good con-
dition with no evidence of disease.
Case discussion
This patient was presented with a suspicious mammo-
gram. Due to her age, the first priority was to exclude
breast cancer. It was thus imperative to proceed to biopsy
sampling. The decision of the j-wire biopsy was made
based upon the fact that the nodule was not palpable,
combined with the patient’s large breast size. Primary
histology result (atypical carcinoid tumor) needed further
assessment to clarify whether this tumor was either pri-
mary or secondary, since primary breast carcinoids are
treated mainly with a surgical approach; if this lesion was
a metastatic carcinoid, nothing further was to be done
breast-wise, since metastatic breast carcinoids are simply
removed (lumpectomy) as part of the management plan
required for the primary carcinoid treatment. In
111 -
DTPA - ocreotide scintigraphy is considered an accepted
Figure 1 Pathology sections (×200) of the nodule leading the diagnosis of the atypical carcinoid of the breast: A. hematoxylin-eosin
staining, B. Ki-67/MIB1 staining showing low mitotic activity, C. positive chromogranin and D. positive synaptophysin staining proving the
neuroendocrine origin of the tumor.
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tumor throughout the body [4]. The MDT decision for
modified radical mastectomy is within the treatment
options applied so far in primary atypical carcinoid
tumours. However based on the slow growth rate of such
neoplasms, it could be argued that such an option was an
over-treatment. In our case the option of ALND alone,
combined or not with breast radiotherapy was discussed
with the patient prior to MDT discussion. She opted for
more aggressive surgical treatment in the view of avoid-
ing radiotherapy.
Brief overview of evidence
Primary carcinoid tumors of the breast are considered
rare, representing less than 1% of the breast tumors [3].
Atypical carcinoid breast tumors are expected to exceed
100 reported cases world-wide [5]. Most of the primary
breast carcinoids are found in patients older than 65
years [6].
Primary carcinoid tumors of the breast are neuroendo-
crine tumors [1]. In accordance to carcinoids developed
in other sites, they are classified as “typical” or “atypical”
depending on the degree of cellular differentiation
recognized on the specimen. The first category is char-
acterized by neuroendocrine differentiation with classical
histological architecture of cellular neuroendocrine clus-
ters and sparse mitoses [7]. The second category refers
to poorly differentiated neuroendocrine tissue with an
increased mitotic index [7].
Histology reveals a uniform population of eosinophilic
cells with round nuclei characterized by “salt-and-
pepper” chromatin [3]. The cells seem to be organized
either in nests or in strands mimicking either ductal or
lobular carcinomas. Immunohistochemistry usually
reveals positive reactivity for neuron specific enolase
(NSE), synaptophysin and chromogranin.
The diagnostic approach of breast carcinoid tumors is
the same one applied to any breast lesion. Clinical
examination may or may not reveal a palpable nodule.
Mammography is the imaging method of choice. Mam-
mographic findings are those of neuroendocrine breast
tumors, including dense nodules featured by well-
circumscribed or irregular margins, with or without
microcalcifications [8,9]. The heterogeneity of the mam-
mographic findings can introduce difficulties in discri-
minating a carcinoid tumor from breast cancer. In case
of clinical suspicion, however, caution is needed in
order to avoid provoking a carcinoid crisis as the result
of breast compression during mammography [10].
Tumor sampling by fine needle aspiration and cytology
cannot always exclude invasive carcinoma [11]. In that
case immunocytochemistry can assist in the diagnosis
[11]. However the risk of misdiagnosing a carcinoid
tumor, an incident that may lead the clinician to more
aggressive management, has supported the adoption of
either core [12] or excisional biopsy as the gold standard
for diagnosing such tumors.
Treatment is primarily surgery ranging from breast
conserving surgery or mastectomy followed by axillary
lymph-node dissection to modified radical mastectomy
[3,6,13]. Radiotherapy is a controversial therapeutic
option in primary breast carcinoids [3,7]. However,
radiotherapy can be justified if we admit that primary
carcinoids are treated in terms similar to primary breast
cancer. No report has been made so far, regarding either
adjuvant chemotherapy or somatostatin analogues in
primary breast carcinoid tumors.
To date there is no standardized treatment regarding
carcinoid tumors of the breast. In most cases carcinoid
tumors are approached as infiltrative carcinomas of the
breast. Additionally, the reported follow-up intervals are
rather short (less than 5 years), thus it is almost impos-
sible to extract conclusions about treatment efficacy and
prognosis.
Conclusions
Primary atypical carcinoid of the breast is a rare entity. Its
diagnosis requires exclusion of this being a metastasis ori-
ginating from a primary carcinoid located elsewhere in the
body. Treatment is mainly surgical. A multi-centric
approach is needed to organize and evaluate a well-
powered case series to extract significant conclusions
regarding patient management and prognosis.
Figure 2 In
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increased expression of somatostatin receptors throughout the
patient’s body was found.
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Written informed consent was obtained from the patient
for publication of this Case report and any accompany-
ing images. A copy of the written consent is available
for review by the Editor-in-Chief of this journal.
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